This transcript has been edited for clarity.
Michelle O'Donoghue, MD, MPH: Hi. this is Dr Michelle O'Donoghue for Medscape. Joining me today is Dr Dylan Steen in Cincinnati. We're at the American College of Cardiology (ACC) 2022 Scientific Session, which is my first conference postpandemic — or I guess we are still in a pandemic.
One of the more interesting trials will be presented by Dylan, looking at a supermarket strategy toward better eating. This is a topic that's near and dear to my heart because I think that diet and diet interventions are often overlooked in cardiology and can be a path forward for many patients in terms of both quality of life and also making meaningful health impacts. Dylan, why don't you start off with what this trial was about and how you got it up and going?
Dylan L. Steen, MD: Nice to see you again after all this time. For decades now, we've had research collaborations between pharmaceutical biotech, the medical device industry, and independent academic investigators. In fact, here at ACC, we're going to see many of these studies presented.
What has been absent are research collaborations with other industries. In this case, we partnered with the Kroger Company, the largest supermarket chain in the US.
COMMENTARY
SuperWIN: Supermarket Partnership Improves DASH Diet Score
Interviewer: Michelle L. O'Donoghue, MD, MPH; Interviewee: Dylan L. Steen, MD
DisclosuresApril 06, 2022
This transcript has been edited for clarity.
Michelle O'Donoghue, MD, MPH: Hi. this is Dr Michelle O'Donoghue for Medscape. Joining me today is Dr Dylan Steen in Cincinnati. We're at the American College of Cardiology (ACC) 2022 Scientific Session, which is my first conference postpandemic — or I guess we are still in a pandemic.
One of the more interesting trials will be presented by Dylan, looking at a supermarket strategy toward better eating. This is a topic that's near and dear to my heart because I think that diet and diet interventions are often overlooked in cardiology and can be a path forward for many patients in terms of both quality of life and also making meaningful health impacts. Dylan, why don't you start off with what this trial was about and how you got it up and going?
Dylan L. Steen, MD: Nice to see you again after all this time. For decades now, we've had research collaborations between pharmaceutical biotech, the medical device industry, and independent academic investigators. In fact, here at ACC, we're going to see many of these studies presented.
What has been absent are research collaborations with other industries. In this case, we partnered with the Kroger Company, the largest supermarket chain in the US.
© 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SuperWIN: Supermarket Partnership Improves DASH Diet Score - Medscape - Apr 06, 2022.
Tables
Authors and Disclosures
Authors and Disclosures
Interviewer
Michelle L. O'Donoghue, MD, MPH
Senior Investigator, TIMI Study Group; Associate Professor of Medicine, Harvard Medical School; Associate Physician, Brigham and Women's Hospital, Boston, Massachusetts
Disclosure: Michelle L. O'Donoghue, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a consultant for: Novartis; Janssen; CRICO; AstraZeneca; Amgen
Received research grants via Brigham and Women's Hospital from: Amgen; Novartis; AstraZeneca; Janssen; Intarcia; Merck; Pfizer
Received honoraria from: Novartis; AstraZeneca; Amgen; Janssen; Medscape
Prior grants from in past 3 years: AstraZeneca (antiplatelet drug ticagrelor) GlaxoSmithKline (anti-inflammatory drugs no longer in development: losmapimod and darapladib); Merck (osteoporosis drug no longer in development: odanacatib); Amgen (osteoporosis drug romosozumab); Janssen (diabetes drug canagliflozin)
Current grants from: Novartis (lipid lowering drug inclisiran); Amgen (lipid-lowering drug evolocumab; drug that lowers certain lipoprotein) AstraZeneca/Medimmune (drug that blocks inflammatory receptor)
Consulting: Novartis (lipid-lowering drug); Janssen (education); CRICO AstraZeneca (data safety monitoring board for gout and cardiovascular drug); Amgen (drug that lowers certain lipoprotein)
Honoraria: Medscape Cardiology
The opinions expressed in this article are solely my own and do not necessarily reflect the views and opinions of Brigham and Women's Hospital.
Interviewee
Dylan L. Steen, MD
Adjunct Associate Professor, Division of Cardiovascular Health and Disease; Director of Clinical Trials and Population Research, University of Cincinnati Heart, Lung, and Vascular Institute, University of Cincinnati College of Medicine, Cincinnati, Ohio
Disclosure: Dylan L. Steen, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: High Enroll; Sanofi
Received research grant from: The Kroger Company